shRNA screening identifies JMJD1C as being required for leukemia maintenance

Blood, American Society of Hematology, ISSN 1528-0020

Volume 123, 12, 2014

DOI:10.1182/blood-2013-08-522094, Dimensions: pub.1052767243, PMID: 24501218,


Miyagi, Satoru (1) (2) (3)
Porse, Bo (1) (3) (4)
Helin, Kristian (1) (2) (3)



  1. (1) Biotech Research and Innovation Centre,
  2. (2) Centre for Epigenetics, and
  3. (3) University of Copenhagen, grid.5254.6, KU
  4. (4) Rigshospitalet, grid.475435.4, Capital Region
  5. (5) Karolinska Institute, grid.4714.6







Epigenetic regulatory mechanisms are implicated in the pathogenesis of acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL). Recent progress suggests that proteins involved in epigenetic control are amenable to drug intervention, but little is known about the cancer-specific dependency on epigenetic regulators for cell survival and proliferation. We used a mouse model of human AML induced by the MLL-AF9 fusion oncogene and an epigenetic short hairpin RNA (shRNA) library to screen for novel potential drug targets. As a counter-screen for general toxicity of shRNAs, we used normal mouse bone marrow cells. One of the best candidate drug targets identified in these screens was Jmjd1c. Depletion of Jmjd1c impairs growth and colony formation of mouse MLL-AF9 cells in vitro as well as establishment of leukemia after transplantation. Depletion of JMJD1C impairs expansion and colony formation of human leukemic cell lines, with the strongest effect observed in the MLL-rearranged ALL cell line SEM. In both mouse and human leukemic cells, the growth defect upon JMJD1C depletion appears to be primarily due to increased apoptosis, which implicates JMJD1C as a potential therapeutic target in leukemia.


Funders and Grants

Research Categories

Main Subject Area

Fields of Research

Links & Metrics

NORA University Profiles

University of Copenhagen

Dimensions Citation Indicators

Times Cited: 51

Field Citation Ratio (FCR): 10.6

Relative Citation ratio (RCR): 1.64